Pasithea Therapeutics Corp. (KTTA) Stock Score, Valuation & Financial Research

Pasithea Therapeutics Corp. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for KTTA

Pasithea Therapeutics Corp. does not currently have a complete Wall Street Score. The stored market price is USD 0.45. These figures are a research snapshot, not a buy or sell recommendation.

What Pasithea Therapeutics Corp. does

Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Pasithea Therapeutics Corp. is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the discovery, research, and development of innovative treatments for central nervous system disorders and other diseases, relying on capital raises to fund its ongoing research and development activities.

Products and services

  • The company's primary product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase (MEK) inhibitor designed to address limitations of existing drugs targeting similar mechanisms.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its drug candidates for clinical trials. Source

Business strengths to evaluate

  • Focus on next-generation macrocyclic MEK inhibitor technology Source

Business risks and research considerations

  • History of operating losses and no revenue from product sales Source
  • Dependence on the success of clinical-stage product candidates Source
  • Reliance on third-party manufacturers and service providers Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

KTTA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.45
Market capitalization:
14.94M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -21.29M
Free cash flow:
USD -15.21M
Cash:
USD 45.66B
Total debt:
USD 0.00
EPS:
USD -2.46

What stands out

  • Free cash flow is USD -15.21M, negative for the stored period.
  • The balance sheet shows USD 45.66B of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 45.66B using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for KTTA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can KTTA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is KTTA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for KTTA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of KTTA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research KTTA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.